Elixa Medicaments Profile
Key Indicators
- Authorised Capital ₹ 4.50 M
- Paid Up Capital ₹ 1.17 M
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 82.05%
- Profit Growth 16.16%
- Ebitda -304.16%
- Net Worth 7.13%
- Total Assets 19.12%
About Elixa Medicaments
Elixa Medicaments Private Limited (EMPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 October 2017 (Seven years and four months 1 days old ). Its registered office is in Kolhapur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 4.50 M and a paid-up capital of Rs 1.17 M, as per Ministry of Corporate Affairs (MCA) records.
Rashmi Deshpande and Rajiv Deshpande serve as directors at the Company.
Company Details
-
Location
Kolhapur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U33309PN2017PTC172931
-
Company No.
172931
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Oct 2017
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Elixa Medicaments?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rashmi Deshpande
|
Director | 10-Oct-2017 | Current |
|
Rajiv Deshpande
|
Director | 18-Mar-2020 | Current |
Financial Performance of Elixa Medicaments.
Elixa Medicaments Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 82.05% increase. The company also saw a substantial improvement in profitability, with a 16.16% increase in profit. The company's net worth moved up by a moderate rise of 7.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elixa Medicaments?
In 2019, Elixa Medicaments had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Elixa Medicaments?
Unlock and access historical data on people associated with Elixa Medicaments, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elixa Medicaments, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elixa Medicaments's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
